{"id":380903,"date":"2020-11-13T09:28:26","date_gmt":"2020-11-13T14:28:26","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380903"},"modified":"2020-11-13T09:28:26","modified_gmt":"2020-11-13T14:28:26","slug":"anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\/","title":{"rendered":"AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference"},"content":{"rendered":"
\n

SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the 2020 Jefferies London Virtual Healthcare Conference on Tuesday, November 17, 2020, at 12:35 p.m. ET. The conference will be conducted virtually, and the presentation will be available via https:\/\/wsw.com\/webcast\/jef<\/a>f<\/a>141\/anab\/1804050<\/a><\/p>\n

A live webcast of the presentation will also be available through the investor section\u00a0of the AnaptysBio website at https:\/\/ir.anapty<\/a>s<\/a>bio.com\/events<\/a>. A replay of the webcast will be available for 90 days following the event.<\/p>\n

\n About AnaptysBio<\/strong>
\n
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. The Company\u2019s proprietary anti-inflammatory pipeline includes its anti-IL-36R antibody imsidolimab, previously referred to as ANB019, for the treatment of rare inflammatory diseases, including generalized pustular psoriasis, or GPP, palmoplantar pustulosis, or PPP, EGFRi and ichthyosis; its anti-PD-1 agonist program, ANB030, for treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated; its BTLA modulator program, ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation; and its anti-IL-33 antibody etokimab, previously referred to as ANB020, for the treatment of chronic rhinosinusitis with nasal polyps, or CRSwNP, and eosinophilic asthma. AnaptysBio\u2019s antibody pipeline has been developed using its proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GlaxoSmithKline, including an anti-PD-1 antagonist antibody (dostarlimab GSK4057190A), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889A) and an anti-LAG-3 antagonist antibody (GSK4074386), and an inflammation collaboration with Bristol-Myers Squibb, including an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in clinical development.<\/p>\n

\n Contact:<\/strong>
\n
Dennis Mulroy
AnaptysBio, Inc.
858.732.0201
dmulroy@anaptysbio.com<\/a><\/p>\n

\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the 2020 Jefferies London Virtual Healthcare Conference on Tuesday, November 17, 2020, at 12:35 p.m. ET. The conference will be conducted virtually, and the presentation will be available via https:\/\/wsw.com\/webcast\/jeff141\/anab\/1804050 A live webcast of the presentation will also be available through the investor section\u00a0of the AnaptysBio website at https:\/\/ir.anaptysbio.com\/events. A replay of the webcast will be available for 90 days following the event. About AnaptysBio AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody … <\/p>\n

Continue reading “AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-380903","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the 2020 Jefferies London Virtual Healthcare Conference on Tuesday, November 17, 2020, at 12:35 p.m. ET. The conference will be conducted virtually, and the presentation will be available via https:\/\/wsw.com\/webcast\/jeff141\/anab\/1804050 A live webcast of the presentation will also be available through the investor section\u00a0of the AnaptysBio website at https:\/\/ir.anaptysbio.com\/events. A replay of the webcast will be available for 90 days following the event. About AnaptysBio AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody … Continue reading "AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-13T14:28:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTUwMyMzODI1NDQxIzIwMjAxMjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference\",\"datePublished\":\"2020-11-13T14:28:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\\\/\"},\"wordCount\":354,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTUwMyMzODI1NDQxIzIwMjAxMjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\\\/\",\"name\":\"AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTUwMyMzODI1NDQxIzIwMjAxMjY=\",\"datePublished\":\"2020-11-13T14:28:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTUwMyMzODI1NDQxIzIwMjAxMjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTUwMyMzODI1NDQxIzIwMjAxMjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference - Market Newsdesk","og_description":"SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the 2020 Jefferies London Virtual Healthcare Conference on Tuesday, November 17, 2020, at 12:35 p.m. ET. The conference will be conducted virtually, and the presentation will be available via https:\/\/wsw.com\/webcast\/jeff141\/anab\/1804050 A live webcast of the presentation will also be available through the investor section\u00a0of the AnaptysBio website at https:\/\/ir.anaptysbio.com\/events. A replay of the webcast will be available for 90 days following the event. About AnaptysBio AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody … Continue reading \"AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-13T14:28:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTUwMyMzODI1NDQxIzIwMjAxMjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference","datePublished":"2020-11-13T14:28:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\/"},"wordCount":354,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTUwMyMzODI1NDQxIzIwMjAxMjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\/","name":"AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTUwMyMzODI1NDQxIzIwMjAxMjY=","datePublished":"2020-11-13T14:28:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTUwMyMzODI1NDQxIzIwMjAxMjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTUwMyMzODI1NDQxIzIwMjAxMjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anaptysbio-to-present-at-the-2020-jefferies-london-virtual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AnaptysBio to Present at the 2020 Jefferies London Virtual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380903","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=380903"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380903\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=380903"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=380903"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=380903"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}